KX2-391, protein kinase inhibitor
 

http://www.therapeuticsdaily.com/new...e&channelID=31

The Buffalo-developed drug stood out in nonhuman tests, showing effectiveness in a range of cancers, with fewer toxic side effects. It works in a way uniquely different from other kinase inhibitors under study.

Roswell Park Cancer Institute and M.D. Anderson Cancer Center in Houston are performing the phase one trials, which are expected to enroll 50 patients with advanced cancer who have not responded to other treatments.